EUVIMEDEUVIMED entdecken
Open Access

Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition

Matthew D Galbraith iD, Angela L Rachubinski iD, Keith P Smith iD, Paula Araya iD, Katherine A Waugh, Belinda Enriquez-Estrada, Kayleigh Worek, Ross E Granrath iD, Kohl T Kinning iD, Neetha Paul Eduthan, Michael P Ludwig iD, Elena W Y Hsieh und 2 weitere

Science Advances · 30.06.2023 · 9 (26)

DOI: 10.1126/sciadv.adg6218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 30.06.2023. Verfasst von Matthew D Galbraith und 13 weiteren Autor:innen. Beteiligte Einrichtung: Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Hauptthemen laut MEDLINE: Down Syndrome. Die Arbeit wurde bisher 91-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Individuals with Down syndrome (DS) display chronic hyperactivation of interferon signaling. However, the clinical impacts of interferon hyperactivity in DS are ill-defined. Here, we describe a multiomics investigation of interferon signaling in hundreds of individuals with DS. Using interferon scores derived from the whole blood transcriptome, we defined the proteomic, immune, metabolic, and clinical features associated with interferon hyperactivity in DS. Interferon hyperactivity associates with a distinct proinflammatory phenotype and dysregulation of major growth signaling and morphogenic pathways. Individuals with the highest interferon activity display the strongest remodeling of the peripheral immune system, including increased cytotoxic T cells, B cell depletion, and monocyte activation. Interferon hyperactivity accompanies key metabolic changes, most prominently dysregulated tryptophan catabolism. High interferon signaling stratifies a subpopulation with elevated rates of congenital heart disease and autoimmunity. Last, a longitudinal case study demonstrated that JAK inhibition normalizes interferon signatures with therapeutic benefit in DS. Together, these results justify the testing of immune-modulatory therapies in DS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Down SyndromeHumansProteomicsInterferonsAutoimmunitySignal Transduction

Substanzen

Interferons

Autor:innen und Institutionen

  • Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Department of Pediatrics, Section of Developmental Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Department of Pediatrics, Division of Allergy/Immunology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Department of Pediatrics, Section of Developmental Biology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

ORCID-Profile: Matthew D Galbraith, Angela L Rachubinski, Keith P Smith, Paula Araya, Ross E Granrath, Kohl T Kinning, Michael P Ludwig, Kelly D Sullivan, Joaquin M Espinosa

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Galbraith, M. D., Rachubinski, A. L., Smith, K. P., Araya, P., Waugh, K. A., Enriquez-Estrada, B., Worek, K., Granrath, R. E., Kinning, K. T., Paul Eduthan, N., Ludwig, M. P., Hsieh, E. W. Y., Sullivan, K. D., & Espinosa, J. M. (2023). Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition. Science Advances, 9(26). https://doi.org/10.1126/sciadv.adg6218

Vancouver

Galbraith MD, Rachubinski AL, Smith KP, Araya P, Waugh KA, Enriquez-Estrada B, et al. Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition. Science Advances. 2023;9(26). doi:10.1126/sciadv.adg6218

BibTeX
@article{Galbraith2023,
  author = {Galbraith, Matthew D and Rachubinski, Angela L and Smith, Keith P and Araya, Paula and Waugh, Katherine A and Enriquez-Estrada, Belinda and Worek, Kayleigh and Granrath, Ross E and Kinning, Kohl T and Paul Eduthan, Neetha and Ludwig, Michael P and Hsieh, Elena W Y and Sullivan, Kelly D and Espinosa, Joaquin M},
  title = {Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition},
  journal = {Science Advances},
  year = {2023},
  volume = {9},
  number = {26},
  doi = {10.1126/sciadv.adg6218}
}
Kostenlos starten →